Nextremity Solutions, Inc. Receives FDA 510(k) Clearance for Cannulated Hammertoe System

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Nextremity Solutions, Inc. Receives FDA 510(k) Clearance for Cannulated Hammertoe System

Nextremity announces 510(k) clearance by the Food & Drug Administration for its upcoming DuoHex™ CH System.

PR Newswire

WARSAW, Ind., July 3, 2020 /PRNewswire-PRWeb/ -- Nextremity Solutions, Inc., a strategic commercialization organization with a focus on the extremity musculoskeletal space, located in "The Orthopedic Capital of the World," Warsaw, Ind., today announced it has received 510(k) clearance by the Food & Drug Administration to market its upcoming DuoHex™ CH System.

"Designed with an optimized array of implant threads for a variety of patient anatomy, a fully-guided cannulated system, and in-situ adjustment, the DuoHex CH system provides an exciting new technology for both patients and surgeons," said Thomas Holton, Senior Engineer, Product Development for Nextremity Solutions.

The DuoHex CH System addresses hammertoe deformity in patients and provides surgeons with a novel two-piece threaded implant construct is designed for optimum bone purchase. The design of the cannulated implants and instruments provide targeting and technique guidance for repeatable outcomes. The implant-to-implant rotational stability is made possible thanks to the implant's innovative hexagonal locking mechanism.

Ryan Schlotterback, Chief Technology Officer for Nextremity Solutions said, "Nextremity Solutions was founded years ago by surgeons with a passion for the foot and ankle market and with an innovative solution for hammertoe correction. After all this time, it was fun to revisit this common foot procedure and have the engineers go back to the drawing board. The team has done a fantastic job of taking our rich heritage and combining all we've learned over the years to commercialize another great solution for hammertoe correction. We're excited about adding the DuoHex CH System to our rapidly expanding portfolio."

"Once again, I am so proud of our team as we received our twelfth 510k approval to support yet another global solution to unmet needs of foot and ankle surgeons and their patients. We remain committed to our mission of becoming the premier Strategic Commercialization Company in the Extremity, Trauma, Sports Medicine and Joint Preservation market," President & CEO, Rod K. Mayer added.

The Nextremity Solutions DuoHex CH Cannulated Hammertoe System is indicated for small bone reconstruction limited to interphalangeal repair and fusion of the lesser toes.

About Nextremity Solutions, Inc.
Nextremity Solutions, Inc. is a privately held strategic commercialization organization in the musculoskeletal space, offering innovative solutions and Revenue Ready products for various musculoskeletal applications and for the benefit of its industry partners. The Company's procedure-ready, sterile implant systems include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.

For further information, visit http://www.nextremitysolutions.com or call Dave Temple, Director of Marketing & Corporate Communications at 574-635-3022.

 

SOURCE Nextremity Solutions, Inc.

Copyright CNW Group 2020

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).